Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celera and the 'logic of biology'

As it races to complete and make public the raw human genome sequence, Celera Genomics Corp. recently has taken back-of-the-hand shots from academic competitors and their sympathizers in the White House and 10 Downing Street. But the real question is how CRA will add value to its databases long after the hullabaloo over the publicly available raw sequence dies down.

Thus the company's acquisition

Read the full 632 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE